Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heat-stable carbetocin versus oxytocin for first-line treatment of atonic postpartum haemorrhage
ACTRN12623001348640Phase 3Recruiting
- Sponsor
- World Health Organization
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in postpartum hemorrhage (PPH) comparing Intravenous heat-stable carbetocin with Intravenous oxytocin (2 arms). Primary endpoint: Proportion with additional blood loss greater than or equal to 500 mL. Started Apr 2024; status: recruiting.
02
Drugs
heat-stable carbetocinoxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on ACTRN12623001348640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001348640.